Cyproheptadine
From Wikipedia, the free encyclopedia
 | |
|---|---|
 | |
| Systematic (IUPAC) name | |
| 4-(5H-dibenzo [a,d]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride | |
| Clinical data | |
| Trade names | Periactin |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a682541 |
| Licence data | US Daily Med:link |
| Pregnancy cat. | A (AU) B (US) |
| Legal status | Pharmacist Only (S3) (AU) POM (UK) |
| Routes | Oral |
| Pharmacokinetic data | |
| Protein binding | 96 to 99% |
| Metabolism | Hepatic[1][2] |
| Half-life | 8.6 hours[3] |
| Excretion | Faecal (2-20%; 34% of this as unchanged drug) and renal (40%; none as unchanged drug)[1][2] |
| Identifiers | |
| CAS number | 129-03-3  969-33-5 (hydrochloride) |
| ATC code | R06AX02 |
| PubChem | CID 2913 |
| IUPHAR ligand | 277 |
| DrugBank | DB00434 |
| ChemSpider | 2810 |
| UNII | 2YHB6175DO |
| KEGG | D07765 |
| ChEBI | CHEBI:4046 |
| ChEMBL | CHEMBL516 |
| Chemical data | |
| Formula | C21H21N |
| Mol. mass | 287.398 g/mol |
| SMILES
| |
| |
| (what is this?) (verify) | |
Cyproheptadine /ˌsaɪprɵˈhɛptədiːn/, sold under the brand name Periactin or Peritol, is a first-generation antihistamine with additional anticholinergic, antiserotonergic, and local anesthetic properties.
Indications
Periactin (cyproheptadine) 4 mg tablets
- Cyproheptadine is used to treat allergic reactions (specifically hay fever).[4]
- Has shown effectiveness in the treatment of nightmares including nightmares related to post traumatic stress disorder.[5][6]
- Has been used in the management of moderate to severe cases of serotonin syndrome (a complex of symptoms associated with the use of serotonergic drugs,[7] such as selective serotonin reuptake inhibitors and monoamine oxidase inhibitors),[8][9][10] and in cases of hyperserotoninaemia resulting from a serotonin-producing carcinoid tumour[11][12]
- Can also be used as a preventive measure against migraine in children and adolescents.[13][14][15][16][17] In Australia this is the only indication for which cyproheptadine is subsidised by the PBS.[7]
- Can relieve SSRI-induced sexual dysfunction[18][19] and drug-induced hyperhidrosis (excessive sweating).[20]
- Also used in the treatment of cyclical vomiting syndrome[21]
- Long-term use of the drug can stimulate the appetite and may lead to weight gain, which is helpful for underweight people.[22]
- According to a small study, cyproheptadine hydrochloride has been found to improve sleep, calmness, as well as mood and energy levels, and to improve both negative and (sometimes even) positive psychotic symptoms in a subgroup of chronic schizophrenics who do not respond (either completely or sufficiently) to other therapies.[23]
- Cyproheptadine may improve akathisia in patients on antipsychotic medications.[24]
- In clinical trials in which cyproheptadine was used as an adjunct to antipsychotic treatment for patients with schizophrenia, an improvement in negative symptoms was seen.[25][26][27][28][29]
Adverse effects
- Sedation and sleepiness (often transient)
- Dizziness
- Disturbed coordination
- Confusion
- Restlessness
- Excitation
- Nervousness
- Tremor
- Irritability
- Insomnia
- Paraesthesias
- Neuritis
- Convulsions
- Euphoria
- Hallucinations
- Hysteria
- Faintness
- Allergic manifestation of rash and oedema
- Diphoresis
- Urticaria
- Photosensitivity
- Acute labyrinthitis
- Diplopia (seeing double)
- Vertigo
- Tinnitus
- Hypotension (low blood pressure)
- Palpitation
- Extrasystoles
- Anaphylactic shock
- Haemolytic anemia
- Blood dyscarsias such as leukopenia, agranulocytosis and thrombocytopaenia
- Cholestasis
- Hepatic (liver) side effects such as:
- Epigastric distress
- Anorexia
- Nausea
- Vomiting
- Diarrhoea
- Anticholinergic side effects such as:
- - Blurred vision
- - Constipation
- - Xerostomia (dry mouth)
- - Tachycardia (high heart rate)
- - Urinary retention
- - Difficulty passing urine
- - Nasal congestion
- - Nasal or throat dryness
- Urinary frequency
- Early menses
- Thickening of bronchial secretions
- Tightness of chest and wheezing
- Fatigue
- Chills
- Headache
- Increased appetite
- Weight gain
Research has shown a suppression of growth hormone with doses of 8–12 mg per day taken for 5 days.[30]
Overdose
Supportative measures such as gastric lavage or induced emesis are usually recommended in cases of overdose. The symptoms are usually indicative of CNS depression (or conversely CNS stimulation in some) and excess anticholinergic side effects. The LD50 in mice is 123 mg/kg and 295 mg/kg in rats.[1][2]
Pharmacology
Cyproheptadine is known to be an antagonist (or inverse agonist depending on the site in question) of the receptors listed in the table below.
| Receptor/Transporter Protein | Binding affinity (Ki[nM]) towards cloned human receptors unless otherwise specified[31] |
|---|---|
| SERT | 4100 (RC) |
| NET | 290 (RC) |
| 5-HT1A | 59 |
| 5-HT2A | 1.67 |
| 5-HT2B | 1.54 |
| 5-HT2C | 2.23 |
| 5-HT3 | 228 (MN) |
| 5-HT6 | 142 |
| 5-HT7 | 123.01 |
| M1 | 12 |
| M2 | 7 |
| M3 | 12 |
| M4 | 8 |
| M5 | 11.8 |
| D1 | 117 |
| D2 | 112 |
| D3 | 8 |
| H1 | 0.06 |
| H3 | >10000 |
| H4 | 201.5 |
Acronyms used:
RC - Cloned rat receptor.
MN - Mouse NG108-15 receptor.
Pharmacokinetics
Cyproheptadine is well-absorbed following oral ingestion, with peak plasma levels occurring after 1–3 hours.[32] Its half-life when taken orally is approximately 8 hours.[3]
Veterinary use
Cyproheptadine is used in cats as an appetite stimulant and as an adjunct in the treatment of asthma.[33][34] Possible adverse effects include excitement and aggressive behavior.[33] The elimination half-life of cyproheptadine in cats is 12 hours.[34]
Cyproheptadine has been used successfully in treatment of Pituitary Pars Intermedia Dysfunction (PPID) in horses.[35]
References
- ↑ 1.0 1.1 1.2 1.3 "CYPROHEPTADINE HYDROCHLORIDE tablet [Boscogen, Inc.]" (PDF). DailyMed. Boscogen, Inc. November 2010. Retrieved 26 October 2013.
- ↑ 2.0 2.1 2.2 2.3 "PRODUCT INFORMATION PERIACTIN® (cyproheptadine hydrochloride)". Aspen Pharmacare Australia. Aspen Pharmacare Australia Pty Ltd. 17 November 2011. Retrieved 26 October 2013.
- ↑ 3.0 3.1 Gunja N, Collins M, Graudins A (2004). "A comparison of the pharmacokinetics of oral and sublingual cyproheptadine". Journal of Toxicology. Clinical Toxicology 42 (1): 79–83. PMID 15083941.
- ↑ MedlinePlus Drug Information: Cyproheptadine
- ↑ Rijnders, R. J.P.; Laman, DM; Van Diujn, H (2000). "Cyproheptadine for Posttraumatic Nightmares". American Journal of Psychiatry 157 (9): 1524–a. doi:10.1176/appi.ajp.157.9.1524-a. PMID 10964879.
- ↑ Gupta, S; Popli, A; Bathurst, E; Hennig, L; Droney, T; Keller, P (May 1998). "Efficacy of cyproheptadine for nightmares associated with posttraumatic stress disorder". Comprehensive Psychiatry 39 (3): 160–4. doi:10.1016/S0010-440X(98)90076-1. ISSN 0010-440X. PMID 9606583.
- ↑ 7.0 7.1 Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
- ↑ Mills KC (October 1995). "Serotonin syndrome". American Family Physician 52 (5): 1475–82. PMID 7572570.
- ↑ Gillman PK (1999). "The serotonin syndrome and its treatment". Journal of Psychopharmacology (Oxford, England) 13 (1): 100–9. doi:10.1177/026988119901300111. PMID 10221364.
- ↑ Hall M, Buckley N (2003). "Serotonin syndrome". Australian Prescriber 26 (3): 62–3.
- ↑ Berry EM, Maunder C, Wilson M (January 1974). "Carcinoid myopathy and treatment with cyproheptadine (Periactin)". Gut 15 (1): 34–8. doi:10.1136/gut.15.1.34. PMC 1412931. PMID 4274414.
- ↑ Moertel, Charles G.; Kvols, LK; Rubin, J (1991). "A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome". Cancer 67 (1): 33–6. doi:10.1002/1097-0142(19910101)67:1<33::AID-CNCR2820670107>3.0.CO;2-E. PMID 1985720.
- ↑ Wendy G Mitchell et al. (2006). "Childhood Migraine Variants".
- ↑ UVA Neurogram: Treatment of Pediatric Migraine
- ↑ Netdoctor: Periactin
- ↑ Migraines in Children and Adolescents
- ↑ Klimek A (1979). "Cyproheptadine (Peritol) in the treatment of migraine and related headache". Ther Hung 27 (2): 93–4. PMID 494146.
- ↑ Keller Ashton A, Hamer R, Rosen RC (1997). "Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large-scale retrospective study of 596 psychiatric outpatients". Journal of Sex & Marital Therapy 23 (3): 165–75. doi:10.1080/00926239708403922. PMID 9292832.
- ↑ McCormick S, Olin J, Brotman AW (September 1990). "Reversal of fluoxetine-induced anorgasmia by cyproheptadine in two patients". Journal of Clinical Psychiatry 51 (9): 383–4. PMID 2211550.
- ↑ Ashton AK, Weinstein WL (May 2002). "Cyproheptadine for drug-induced sweating". American Journal of Psychiatry 159 (5): 874–5. doi:10.1176/appi.ajp.159.5.874-a. PMID 11986151.
- ↑ Andersen JM, Sugerman KS, Lockhart JR, Weinberg WA (December 1997). "Effective Prophylactic Therapy for Cyclic Vomiting Syndrome in Children Using Amitriptyline or Cyproheptadine". Pediatrics 100 (6): 977–981. doi:10.1542/peds.100.6.977. PMID 9374568.
- ↑ Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis | Wiley Online Library
- ↑ "Cyproheptadine, Human Health Effects". Toxicology Data Network. 2003. Retrieved 8 November 2012.
- ↑ Taylor, D; Paton, C; Shitij, K (2012). Maudsley Prescribing Guidelines in Psychiatry (in English) (11th ed.). West Sussex: Wiley-Blackwell. p. 104, 605. ISBN 978-0470979488.
- ↑ Silver, H; Blacker, M; Weller, MPI; Lerer, B (February 1989). "Treatment of chronic schizophrenia with cyproheptadine". Biological Psychiatry 25 (4). doi:10.1016/0006-3223(89)90206-0.
- ↑ Silver, H; Blacker, M; Weller, MPI; Lerer, B (September 1991). "Treatment of chronic schizophrenia with cyproheptadine: A double-blind placebo-controlled study". Biological Psychiatry 30 (5): 523–525. doi:10.1016/0006-3223(91)90317-F.
- ↑ Lee, HS; Song, DH; Kim, JH; Lee, YM; Han, ES; Yoo, KJ (June 1995). "Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study". International Clinical Psychopharmacology 10 (2): 67–72. PMID 7673658.
- ↑ Kapur, S; Zipursky, RB; Remington, G. "Do loxapine plus cyproheptadine make an atypical antipsychotic? PET analysis of their dopamine D2 and serotonin2 receptor occupancy". Archives of General Psychiatry 55 (7): 666–668. PMID 9672060.
- ↑ Akhondzadeh, S; Mohammadi, MR; Amini-Nooshabadi, H; Davari-Ashtiani, R (February 1999). "Cyproheptadine in treatment of chronic schizophrenia:a double-blind, placebo-controlled study". Journal of Clinical Pharmacy and Therapeutics 24 (1): 49–52. doi:10.1046/j.1365-2710.1999.00197.x. PMID 10319907.
- ↑ Rosskamp RH, Haverkamp F, von Kalckreuth G (May 1990). "The effect of cyproheptadine on plasma growth hormone (GH) and on somatostatin response to GH-releasing hormone in man". Horm. Metab. Res. 22 (5): 295–7. doi:10.1055/s-2007-1004905. PMID 1971804.
- ↑ Roth BL, Driscol J (12 January 2011). "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 26 October 2013.
- ↑ Lindsay Murray; Frank Daly; David McCoubrie; Mike Cadogan (15 January 2011). Toxicology Handbook. Elsevier Australia. p. 388. ISBN 978-0-7295-3939-5. Retrieved 27 November 2011.
- ↑ 33.0 33.1 Dowling PM (February 8, 2005). "Drugs Affecting Appetite". In Kahn CM, Line S, Aiello SE (eds.). The Merck Veterinary Manual (9th ed.). John Wiley & Sons. ISBN 0-911910-50-6. Retrieved on October 26, 2008.
- ↑ 34.0 34.1 Dowling PM (February 8, 2005). "Systemic Therapy of Airway Disease: Cyproheptadine". In Kahn CM, Line S, Aiello SE (eds.). The Merck Veterinary Manual (9th ed.). John Wiley & Sons. ISBN 0-911910-50-6. Retrieved on October 26, 2008.
- ↑ Merck Vet Manual. "Hirsutism Associated with Adenomas of the Pars Intermedia". Retrieved April 24, 2011.
| ||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||
| ||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.